ERBB2 and breast cancer: The primary analysis of the ongoing DEBBRAH trial29 showed that the CNS-ORR of T-DXd in 13 BC patients with HER2-positive and active BM was 46.2% (50.0% in asymptomatic untreated BMs and 44.4% in progressing BMs after local therapy), and the PFS was immature.